Has Kari Murphy, APRN received payments from drug or device companies?

Yes. Drug and device makers reported $4,695 in general payments to Kari Murphy, APRN across 149 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Kari Murphy, APRN did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Kari Murphy, APRN come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Kari Murphy, APRN

Psychiatric/Mental Health · Tulsa, OKNPI 1336548049

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.9% of the total across 149 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations.

$4,695in general payments, 2019–2025

Across 149 payments — averaging $31.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$1K
Otsuka America Pharmaceutical, Inc.$615
Indivior Inc.$561
AbbVie$512
Neurocrine Biosciences, Inc.$441
Axsome Therapeutics, Inc.$395
plus $1K from 6 others

What the payments were for

Food & beverage$4,690100%
Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson	23	$1,056
Otsuka America Pharmaceutical, Inc.	15	$615
Indivior Inc.	30	$561
AbbVie	11	$512
Neurocrine Biosciences, Inc.	13	$441
Axsome Therapeutics, Inc.	10	$395
Alkermes, Inc.	21	$370
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	7	$236
Vanda Pharmaceuticals Inc.	3	$215
Lundbeck LLC	8	$136
Teva Pharmaceuticals USA, Inc.	5	$104
Noven Therapeutics, LLC	3	$53

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,695 in reported general payments places this provider in the 80th percentile of 231 psychiatric/mental health providers in Oklahoma.

See all psychiatric/mental health providers in Oklahoma →

Medicare billing

Part B allowed, 2024

$8,672

Medicare patients

Services billed

113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Abilify MaintenaAripiprazole	34	$95,666
Invega SustennaPaliperidone Palmitate	15	$35,695
VraylarCariprazine Hcl	15	$31,028
Lurasidone Hcl	14	$2,224
Bupropion XlBupropion Hcl	107	$1,298
Quetiapine Fumarate	101	$1,278
Mirtazapine	88	$1,216
Duloxetine Hcl	64	$1,049
Aripiprazole	49	$747
Olanzapine OdtOlanzapine	19	$690
Trazodone Hcl	100	$677
Olanzapine	39	$591
Hydroxyzine Hcl	37	$565
Divalproex Sodium ErDivalproex Sodium	28	$563
Doxepin Hcl	30	$555

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena	$615	$95,66634 claims
Johnson & JohnsonInvega Sustenna	$1,056	$35,69515 claims
AbbVieVraylar	$512	$31,02815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 231 psychiatric/mental health providers in Oklahoma.

Other psychiatric/mental health in Tulsa

See the full list for Oklahoma →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →